Literature DB >> 25701451

Immuno-modulatory strategies for reduction of HIV reservoir cells.

H T Banks1, Kevin B Flores2, Shuhua Hu2, Eric Rosenberg3, Maria Buzon3, Xu Yu3, Matthias Lichterfeld3.   

Abstract

Antiretroviral therapy is able to suppress the viral load to below the detection limit, but it is not able to eradicate HIV reservoirs. Thus, there is a critical need for a novel treatment to eradicate (or reduce) the reservoir in order to eliminate the need for a lifelong adherence to antiretroviral therapy, which is expensive and potentially toxic. In this paper, we investigate the possible pharmacological strategies or combinations of strategies that may be beneficial to reduce or possibly eradicate the latent reservoir. We do this via studies with a validated mathematical model, where the parameter values are obtained with newly acquired clinical data for HIV patients. Our findings indicate that the strategy of reactivating the reservoir combined with enhancement of the killing rate of HIV-specific CD8+ T cells is able to eradicate the reservoir. In addition, our analysis shows that a targeted suppression of the immune system is also a possible strategy to eradicate the reservoir.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immune response; Inverse problem; Mathematical model; Stability analysis

Mesh:

Substances:

Year:  2015        PMID: 25701451      PMCID: PMC4390551          DOI: 10.1016/j.jtbi.2015.02.006

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  32 in total

Review 1.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

2.  Interferon alfa therapy: toward an improved treatment for HIV infection.

Authors:  Lucy A McNamara; Kathleen L Collins
Journal:  J Infect Dis       Date:  2012-10-26       Impact factor: 5.226

3.  Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.

Authors:  Christina Gavegnano; Mervi Detorio; Catherine Montero; Alberto Bosque; Vicente Planelles; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

5.  Modelling HIV immune response and validation with clinical data.

Authors:  H T Banks; M Davidian; Shuhua Hu; Grace M Kepler; E S Rosenberg
Journal:  J Biol Dyn       Date:  2008-10       Impact factor: 2.179

Review 6.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients.

Authors:  P G Stock; B Barin; H Hatano; R L Rogers; M E Roland; T-H Lee; M Busch; S G Deeks
Journal:  Am J Transplant       Date:  2014-04-03       Impact factor: 8.086

9.  Management of common adverse effects in the era of highly active antiretroviral therapy in south east Ethiopia.

Authors:  Sadikalmahdi Hussen Abdella; Nasir Tajure Wabe; Elias Ali Yesuf
Journal:  N Am J Med Sci       Date:  2011-11

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  3 in total

1.  A Dynamical Modeling Approach for Analysis of Longitudinal Clinical Trials in the Presence of Missing Endpoints.

Authors:  H T Banks; Shuhua Hu; Eric Rosenberg
Journal:  Appl Math Lett       Date:  2016-08-02       Impact factor: 4.055

2.  Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance.

Authors:  Paula Martínez-Román; Celia Crespo-Bermejo; Daniel Valle-Millares; Violeta Lara-Aguilar; Sonia Arca-Lafuente; Luz Martín-Carbonero; Pablo Ryan; Ignacio de Los Santos; María Rosa López-Huertas; Claudia Palladino; María Muñoz-Muñoz; Amanda Fernández-Rodríguez; Mayte Coiras; Verónica Briz
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

3.  Predicting Inter-individual Variability During Lipid Resuscitation of Bupivacaine Cardiotoxicity in Rats: A Virtual Population Modeling Study.

Authors:  Matthew McDaniel; Kevin B Flores; Belinda S Akpa
Journal:  Drugs R D       Date:  2021-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.